Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 11, Pages 1367-1377
Publisher
Elsevier BV
Online
2022-09-30
DOI
10.1016/s1470-2045(22)00555-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS
- (2022) Celine Callens et al. ANALYTICAL CHEMISTRY
- Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
- (2022) Frédérique Berger et al. BMJ Open
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- (2022) Francois-Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer
- (2021) Antonio Llombart-Cussac et al. JAMA Oncology
- A single droplet digital PCR for ESR1 activating mutations detection in plasma
- (2020) Emmanuelle Jeannot et al. ONCOGENE
- ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials
- (2020) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
- (2020) Harold J. Burstein NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 mutations: a new biomarker in breast cancer
- (2019) Marcela Carausu et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
- (2018) Rinath Jeselsohn et al. CANCER CELL
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started